Overall survival with cetuximab every-2-weeks versus standard once-weekly administration schedule for first-line treatment of RAS wild-type metastatic colorectal cancer in patients with left- and right-sided primary tumour location

Saved in:
Bibliographic Details
Published inEuropean journal of cancer (1990) Vol. 180; pp. 85 - 88
Main Authors Kasper, Stefan, Foch, Caroline, Esser, Regina, Lamy, Francois-Xavier, Zhang, Aimar, Cheng, Ann-Lii, Rouyer, Magali, Brodowicz, Thomas, Zielinski, Christoph
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.02.2023
Elsevier Science Ltd
Subjects
Antineoplastic Agents, Immunological - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Cetuximab - therapeutic use
Colonic Neoplasms - drug therapy
Colorectal carcinoma
Colorectal Neoplasms - drug therapy
Colorectal Neoplasms - genetics
Humans
Metastases
Proto-Oncogene Proteins p21(ras)
Rectal Neoplasms - drug therapy
Tumors
Online AccessGet full text

Cover

Author Foch, Caroline
Brodowicz, Thomas
Rouyer, Magali
Zhang, Aimar
Cheng, Ann-Lii
Lamy, Francois-Xavier
Esser, Regina
Zielinski, Christoph
Kasper, Stefan
Author_xml – sequence: 1
  givenname: Stefan
  surname: Kasper
  fullname: Kasper, Stefan
  email: stefan.kasper@uk-essen.de
  organization: West German Cancer Centre, University Hospital Essen, University of Duisburg-Essen, Germany
– sequence: 2
  givenname: Caroline
  surname: Foch
  fullname: Foch, Caroline
  organization: Merck Healthcare KGaA, Darmstadt, Germany
– sequence: 3
  givenname: Regina
  surname: Esser
  fullname: Esser, Regina
  organization: Merck Healthcare KGaA, Darmstadt, Germany
– sequence: 4
  givenname: Francois-Xavier
  surname: Lamy
  fullname: Lamy, Francois-Xavier
  organization: Merck Healthcare KGaA, Darmstadt, Germany
– sequence: 5
  givenname: Aimar
  surname: Zhang
  fullname: Zhang, Aimar
  organization: Merck Serono (Beijing) Pharmaceutical R&D Co., Ltd, Beijing, China
– sequence: 6
  givenname: Ann-Lii
  surname: Cheng
  fullname: Cheng, Ann-Lii
  organization: National Taiwan University Cancer Center, Taipei, Taiwan
– sequence: 7
  givenname: Magali
  surname: Rouyer
  fullname: Rouyer, Magali
  organization: Bordeaux PharmacoEpi, INSERM CIC1401, University of Bordeaux, Bordeaux, France
– sequence: 8
  givenname: Thomas
  surname: Brodowicz
  fullname: Brodowicz, Thomas
  organization: Internal Medicine, Vienna General Hospital and Medical University of Vienna, Austria
– sequence: 9
  givenname: Christoph
  surname: Zielinski
  fullname: Zielinski, Christoph
  organization: Comprehensive Cancer Centre, Vienna General Hospital and Medical University of Vienna, Austria
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36563490$$D View this record in MEDLINE/PubMed
BookMark eNp9UstuEzEUHaEimhZ-gAW6Ehs2DrZnPBlLbKqKl1SpEo-15bHvEAfPONielHxxf6NOE1iwYOXHOffc4-tzUZ1NYcKqesnoklHWvt0scWP0klPOl4wtKWdPqgXrVpLQTvCzakGlkKSjjTyvLlLaUEpXXUOfVed1K9q6kXRR3d_uMGrvIc1x53baw53LazCY599u1D1gwfeEkzvEnwnKIc0JUtaT1dFCmAw-Qn4P2o5ucilHnV2YIJk12tkjDCHC4GLKxLsJIUfUecQpQxjgy9XX0tBbkvdbhBGzLtLZGTDBh4gmF0NGlyYR3ATbApXCdPToccgEihGI7sc6k-QsWtjGYjvuIc9jmCP4YB7tPK-eDtonfHFaL6vvH95_u_5Ebm4_fr6-uiGm7ppMBOtbZiW1jLWdoaJtVtQ0Le2HVd-aupcDL9edMMwyLim13NQcy7a1sh06U19Wb4662xh-zZiyGl0y6L2eMMxJ8ZXoGBNSikJ9_Q91UxxPxV1hSSGatqkPLH5kmRhSijio0wsVo-oQA7VRhxioQwwUY6rEoBS9OknP_Yj2b8mffy-Ed0cCllnsHEaVTBmtQesOU1c2uP_pPwD-78rr
CitedBy_id crossref_primary_10_2217_fon_2023_0282
Cites_doi 10.1016/j.ejca.2020.11.013
10.1093/annonc/mdx175
10.1016/j.clcc.2018.01.007
10.1016/j.clcc.2020.03.003
10.1097/CAD.0000000000000041
10.1200/jco.2016.34.4_suppl.651
10.1093/annonc/mdt116
10.1016/j.clcc.2016.08.005
10.1093/annonc/mdu333.12
ContentType Journal Article
Copyright 2022 Elsevier Ltd
Copyright Elsevier Science Ltd. Feb 2023
Copyright_xml – notice: 2022 Elsevier Ltd
– notice: Copyright Elsevier Science Ltd. Feb 2023
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7TO
7U7
C1K
H94
K9.
NAPCQ
7X8
DOI 10.1016/j.ejca.2022.11.021
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Oncogenes and Growth Factors Abstracts
Toxicology Abstracts
Environmental Sciences and Pollution Management
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
Oncogenes and Growth Factors Abstracts
Toxicology Abstracts
Environmental Sciences and Pollution Management
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1879-0852
EndPage 88
ExternalDocumentID 10_1016_j_ejca_2022_11_021
36563490
S095980492201766X
Genre Letter
Research Support, Non-U.S. Gov't
Correspondence
GroupedDBID ---
--K
--M
.1-
.55
.FO
.GJ
.~1
0R~
1B1
1P~
1RT
1~.
1~5
29G
3O-
4.4
457
4G.
53G
5GY
5RE
5VS
6PF
7-5
71M
8P~
9JM
AABNK
AACTN
AAEDT
AAEDW
AAIAV
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQXK
AAWTL
AAXUO
ABBQC
ABFNM
ABGSF
ABJNI
ABLJU
ABLVK
ABMAC
ABMZM
ABOCM
ABUDA
ABXDB
ABYKQ
ACDAQ
ACIUM
ACPRK
ACRLP
ADBBV
ADEZE
ADMUD
ADUVX
AEBSH
AEHWI
AEKER
AENEX
AEVXI
AFCTW
AFFNX
AFKWA
AFRAH
AFRHN
AFTJW
AFXIZ
AGHFR
AGRDE
AGUBO
AGYEJ
AHHHB
AHPSJ
AIEXJ
AIKHN
AITUG
AJBFU
AJOXV
AJRQY
AJUYK
ALMA_UNASSIGNED_HOLDINGS
AMFUW
AMRAJ
ANZVX
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
BNPGV
CS3
DOVZS
DU5
EBS
EFJIC
EFLBG
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-2
G-Q
GBLVA
HED
HMK
HMO
HVGLF
HZ~
IHE
J1W
K-O
KOM
LCYCR
M29
M41
MO0
N9A
O-L
O9-
OAUVE
OC~
OO-
OZT
P-8
P-9
P2P
PC.
Q38
R2-
RIG
ROL
RPZ
SAE
SCC
SDF
SDG
SDP
SEL
SES
SEW
SPCBC
SSH
SSU
SSZ
T5K
UV1
WUQ
X7M
XPP
Z5R
ZA5
ZGI
ZXP
~G-
AAXKI
AFJKZ
AKRWK
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7TO
7U7
C1K
H94
K9.
NAPCQ
7X8
ID FETCH-LOGICAL-c384t-51b61d90d1168c056470c460bf7b6c3b9f28c085c1d12900d2c32e1296d96f8c3
IEDL.DBID AIKHN
ISSN 0959-8049
IngestDate Sat Oct 05 05:04:31 EDT 2024
Thu Oct 10 22:02:58 EDT 2024
Thu Sep 26 16:30:06 EDT 2024
Sat Sep 28 08:14:43 EDT 2024
Fri Feb 23 02:38:07 EST 2024
IsPeerReviewed true
IsScholarly true
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c384t-51b61d90d1168c056470c460bf7b6c3b9f28c085c1d12900d2c32e1296d96f8c3
Notes SourceType-Other Sources-1
ObjectType-Article-2
content type line 63
ObjectType-Correspondence-1
PMID 36563490
PQID 2795546435
PQPubID 2047469
PageCount 4
ParticipantIDs proquest_miscellaneous_2758115995
proquest_journals_2795546435
crossref_primary_10_1016_j_ejca_2022_11_021
pubmed_primary_36563490
elsevier_sciencedirect_doi_10_1016_j_ejca_2022_11_021
PublicationCentury 2000
PublicationDate February 2023
2023-02-00
20230201
PublicationDateYYYYMMDD 2023-02-01
PublicationDate_xml – month: 02
  year: 2023
  text: February 2023
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: Oxford
PublicationTitle European journal of cancer (1990)
PublicationTitleAlternate Eur J Cancer
PublicationYear 2023
Publisher Elsevier Ltd
Elsevier Science Ltd
Publisher_xml – name: Elsevier Ltd
– name: Elsevier Science Ltd
References Rouyer, Francois, Cunha, Monnereau, Bignon, Jové (bib2) 2018; 17
Brodowicz, Ciuleanu, Radosavljevic, Shacham-Shmueli, Vrbanec, Plate (bib5) 2013; 24
Modest, Schulz, von Weikersthal, Quietzsch, von Einem, Schalhorn (bib10) 2014; 25
Kasper, Meiler, Knipp, Höhler, Reimer, Steinmetz (bib4) 2020; 19
(bib7) April 2021
Arnold, Lueza, Douillard, Peeters, Lenz, Venook (bib9) 2017; 28
Seligmann, Elliott, Richman, Southward, Barrett, Quirke (bib11) 2014; 25
Sahm, Goehler, Hering-Schubert, Janssen, Neumann, Schwittay (bib3) 2016; 34
Japanese Pharmaceuticals and Medical Devices Agency (2022). Package insert. Erbitux (2022)
Kasper, Foch, Messinger, Esser, Lamy, Rothe (bib1) 2021; 144
Cheng, Cornelio, Shen, Price, Yang, Chung (bib6) 2017; 16
Rouyer (10.1016/j.ejca.2022.11.021_bib2) 2018; 17
Seligmann (10.1016/j.ejca.2022.11.021_bib11) 2014; 25
Kasper (10.1016/j.ejca.2022.11.021_bib4) 2020; 19
Sahm (10.1016/j.ejca.2022.11.021_bib3) 2016; 34
(10.1016/j.ejca.2022.11.021_bib7) 2021
Cheng (10.1016/j.ejca.2022.11.021_bib6) 2017; 16
Kasper (10.1016/j.ejca.2022.11.021_bib1) 2021; 144
Brodowicz (10.1016/j.ejca.2022.11.021_bib5) 2013; 24
Modest (10.1016/j.ejca.2022.11.021_bib10) 2014; 25
10.1016/j.ejca.2022.11.021_bib8
Arnold (10.1016/j.ejca.2022.11.021_bib9) 2017; 28
References_xml – volume: 24
  start-page: 1769
  year: 2013
  end-page: 1777
  ident: bib5
  article-title: FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study
  publication-title: Ann Oncol
  contributor:
    fullname: Plate
– volume: 28
  start-page: 1713
  year: 2017
  end-page: 1729
  ident: bib9
  article-title: Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials
  publication-title: Ann Oncol
  contributor:
    fullname: Venook
– volume: 25
  start-page: 212
  year: 2014
  end-page: 218
  ident: bib10
  article-title: Outcome of patients with metastatic colorectal cancer depends on the primary tumour site (midgut vs. hindgut): analysis of the FIRE1-trial (FuFIRI or mIROX as first-line treatment)
  publication-title: Anti Cancer Drugs
  contributor:
    fullname: Schalhorn
– volume: 16
  start-page: e73
  year: 2017
  end-page: e88
  ident: bib6
  article-title: Efficacy, tolerability, and biomarker analyses of once-every-2-weeks cetuximab plus first-line FOLFOX or FOLFIRI in patients with KRAS or all RAS wild-type metastatic colorectal cancer: the phase 2 APEC study
  publication-title: Clin Colorectal Cancer
  contributor:
    fullname: Chung
– volume: 17
  start-page: 129
  year: 2018
  end-page: 139
  ident: bib2
  article-title: Effectiveness of cetuximab as first-line therapy for patients with wild-type KRAS and unresectable metastatic colorectal cancer in real-life practice: results of the EREBUS cohort
  publication-title: Clin Colorectal Cancer
  contributor:
    fullname: Jové
– volume: 19
  start-page: 236
  year: 2020
  end-page: 247
  ident: bib4
  article-title: Biweekly cetuximab plus FOLFOX6 as first-line therapy in patients with RAS wild-type metastatic colorectal cancer: the CEBIFOX trial
  publication-title: Clin Colorectal Cancer
  contributor:
    fullname: Steinmetz
– volume: 34
  start-page: 651
  year: 2016
  ident: bib3
  article-title: Outcome of patients with KRAS exon 2 wildtype (KRAS-wt) metastatic colorectal carcinoma (mCRC) with cetuximab-based first-line treatment in the noninterventional study ERBITAG and impact of comorbidity and age
  publication-title: J Clin Oncol
  contributor:
    fullname: Schwittay
– volume: 25
  start-page: iv172
  year: 2014
  ident: bib11
  article-title: 509PD - primary tumour location (PTL) as a prognostic and predictive factor in advanced colorectal cancer (aCRC): data from 2075 patients (Pts) in randomised trials
  publication-title: Ann Oncol
  contributor:
    fullname: Quirke
– volume: 144
  start-page: 291
  year: 2021
  end-page: 301
  ident: bib1
  article-title: Noninferiority of cetuximab every-2-weeks versus standard once-weekly administration schedule for the first-line treatment of RAS wild-type metastatic colorectal cancer
  publication-title: Eur J Cancer
  contributor:
    fullname: Rothe
– year: April 2021
  ident: bib7
  article-title: Erbitux full prescribing information
– year: 2021
  ident: 10.1016/j.ejca.2022.11.021_bib7
– volume: 144
  start-page: 291
  year: 2021
  ident: 10.1016/j.ejca.2022.11.021_bib1
  article-title: Noninferiority of cetuximab every-2-weeks versus standard once-weekly administration schedule for the first-line treatment of RAS wild-type metastatic colorectal cancer
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2020.11.013
  contributor:
    fullname: Kasper
– volume: 28
  start-page: 1713
  year: 2017
  ident: 10.1016/j.ejca.2022.11.021_bib9
  article-title: Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdx175
  contributor:
    fullname: Arnold
– volume: 17
  start-page: 129
  year: 2018
  ident: 10.1016/j.ejca.2022.11.021_bib2
  article-title: Effectiveness of cetuximab as first-line therapy for patients with wild-type KRAS and unresectable metastatic colorectal cancer in real-life practice: results of the EREBUS cohort
  publication-title: Clin Colorectal Cancer
  doi: 10.1016/j.clcc.2018.01.007
  contributor:
    fullname: Rouyer
– volume: 19
  start-page: 236
  year: 2020
  ident: 10.1016/j.ejca.2022.11.021_bib4
  article-title: Biweekly cetuximab plus FOLFOX6 as first-line therapy in patients with RAS wild-type metastatic colorectal cancer: the CEBIFOX trial
  publication-title: Clin Colorectal Cancer
  doi: 10.1016/j.clcc.2020.03.003
  contributor:
    fullname: Kasper
– volume: 25
  start-page: 212
  year: 2014
  ident: 10.1016/j.ejca.2022.11.021_bib10
  article-title: Outcome of patients with metastatic colorectal cancer depends on the primary tumour site (midgut vs. hindgut): analysis of the FIRE1-trial (FuFIRI or mIROX as first-line treatment)
  publication-title: Anti Cancer Drugs
  doi: 10.1097/CAD.0000000000000041
  contributor:
    fullname: Modest
– volume: 34
  start-page: 651
  year: 2016
  ident: 10.1016/j.ejca.2022.11.021_bib3
  article-title: Outcome of patients with KRAS exon 2 wildtype (KRAS-wt) metastatic colorectal carcinoma (mCRC) with cetuximab-based first-line treatment in the noninterventional study ERBITAG and impact of comorbidity and age
  publication-title: J Clin Oncol
  doi: 10.1200/jco.2016.34.4_suppl.651
  contributor:
    fullname: Sahm
– volume: 24
  start-page: 1769
  year: 2013
  ident: 10.1016/j.ejca.2022.11.021_bib5
  article-title: FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdt116
  contributor:
    fullname: Brodowicz
– volume: 16
  start-page: e73
  year: 2017
  ident: 10.1016/j.ejca.2022.11.021_bib6
  article-title: Efficacy, tolerability, and biomarker analyses of once-every-2-weeks cetuximab plus first-line FOLFOX or FOLFIRI in patients with KRAS or all RAS wild-type metastatic colorectal cancer: the phase 2 APEC study
  publication-title: Clin Colorectal Cancer
  doi: 10.1016/j.clcc.2016.08.005
  contributor:
    fullname: Cheng
– ident: 10.1016/j.ejca.2022.11.021_bib8
– volume: 25
  start-page: iv172
  year: 2014
  ident: 10.1016/j.ejca.2022.11.021_bib11
  article-title: 509PD - primary tumour location (PTL) as a prognostic and predictive factor in advanced colorectal cancer (aCRC): data from 2075 patients (Pts) in randomised trials
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdu333.12
  contributor:
    fullname: Seligmann
SSID ssj0007840
Score 2.4546912
SourceID proquest
crossref
pubmed
elsevier
SourceType Aggregation Database
Index Database
Publisher
StartPage 85
SubjectTerms Antineoplastic Agents, Immunological - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Cetuximab - therapeutic use
Colonic Neoplasms - drug therapy
Colorectal carcinoma
Colorectal Neoplasms - drug therapy
Colorectal Neoplasms - genetics
Humans
Metastases
Proto-Oncogene Proteins p21(ras)
Rectal Neoplasms - drug therapy
Tumors
Title Overall survival with cetuximab every-2-weeks versus standard once-weekly administration schedule for first-line treatment of RAS wild-type metastatic colorectal cancer in patients with left- and right-sided primary tumour location
URI https://dx.doi.org/10.1016/j.ejca.2022.11.021
https://www.ncbi.nlm.nih.gov/pubmed/36563490
https://www.proquest.com/docview/2795546435
https://search.proquest.com/docview/2758115995
Volume 180
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NatwwEBbJBkovpf_dNg1T6K0oa0u2Vz4uoWHbkhSaBvZmZEkGJ15viO0mufR1-xqdseWFHNJDb5Zl47FmNPNpNDNi7KOWReGkEbgsCTSn1EueyxCbQaClFk5pTbnDJ6fJ8jz6uopXO-xozIWhsEqv-wed3mtrf2fmR3N2VZazM_JgKQS4Am3YPElWu2wPzZFQE7a3-PJtebpVyHPV50UOHi98wefODGFe7sJQ-SEhDqmYpwgfsk8P4c_eDh0_ZU88gITFQOMztuPq5-zRid8if8H-fP9FbqYKmg61AMoRkKsVjGu723Ktc3DYf8cFv3HusgGKyugaGD0KQFmMfVd1B_peYV3AdTDapcoB4lwoSoSNnDAqbGPVYVPAj8UZfrCynHy7sHatppSl0gBVx6aRRoIMSdo1lDX4qq7NQGPlipYDEgK9y4DTSaIWroZ6GNB2a_x3IONL5Lxk58effx4tuT_NgRupopbHYZ6ENg1sGCbKIO6K5oGJkiAv5nliZJ4WAm-r2ISWfGOBFUYKh5eJTZNCGfmKTepN7d4wCG3khJMydsJEMreKyp_nSuRaWYRUdso-jTzMPJHZGM12kRHHM-I4rn4y5PiUxSObs3uil6FV-ed7-6NMZH7iN5mYpxT3hyB0yj5su3HK0j6Mrt2mo2dihUA8TfGZ14MsbcmUiK9llAZv_5Ood-wxtuQQV77PJu11594jbGrzA7Z7-Ds88JPjL5xUG5I
link.rule.ids 315,783,787,4509,24128,27936,27937,45597,45691
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1fb9QwDI_GJgEviP8cDDASbyhcm7S99PE0Md3Y7pDYJt1blSap1NG7m9Z2Y5-Yr4HdpiftYTzw1tat6saO_Ytju4x91rIonDQClyWB5lR6yXMZ4mkQaKmFU1pT7fB8kczOo-_LeLnDDoZaGEqr9La_t-mdtfZXxn40x5dlOT6lCJZCgCvQh02SZPmA7SEaSHF27k2PjmeLrUGeqK4uso944QO-dqZP83IXhtoPCfGVmnmK8D7_dB_-7PzQ4VP2xANImPY8PmM7bv2cPZz7LfIX7M-PawozVVC3aAVQj4BCrWBc0_4uVzoHh_RbLviNc79qoKyMtoYhogBUxdiRqlvQdxrrAq6D0S9VDhDnQlEibOSEUWGbqw6bAn5OT_GFleUU24WVazSVLJUGqDs2jTQyZEjTrqBcg-_qWvc8Vq5oOCAj0IUMOP1J1MJl3w8DmnaF3w7kfImdl-z88NvZwYz7vzlwI1XU8DjMk9CmgQ3DRBnEXdEkMFES5MUkT4zM00LgZRWb0FJsLLDCSOHwMLFpUigjX7Hd9Wbt3jAIbeSEkzJ2wkQyt4ran-dK5FpZhFR2xL4MMsw8k9mQzXaRkcQzkjiufjKU-IjFg5izO6qXoVf553P7g05kfuLXmZiklPeHIHTEPm3JOGVpH0av3aale2KFQDxN8Z7XvS5t2ZSIr2WUBm__k6mP7NHsbH6SnRwtjt-xx0iRfY75Ptttrlr3HiFUk3_wU-QvdGYdhg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Overall+survival+with+cetuximab+every-2-weeks+versus+standard+once-weekly+administration+schedule+for+first-line+treatment+of+RAS+wild-type+metastatic+colorectal+cancer+in+patients+with+left-+and+right-sided+primary+tumour+location&rft.jtitle=European+journal+of+cancer+%281990%29&rft.au=Kasper%2C+Stefan&rft.au=Foch%2C+Caroline&rft.au=Esser%2C+Regina&rft.au=Lamy%2C+Francois-Xavier&rft.date=2023-02-01&rft.pub=Elsevier+Ltd&rft.issn=0959-8049&rft.eissn=1879-0852&rft.volume=180&rft.spage=85&rft.epage=88&rft_id=info:doi/10.1016%2Fj.ejca.2022.11.021&rft.externalDocID=S095980492201766X
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0959-8049&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0959-8049&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0959-8049&client=summon